Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study

doi:10.1016/j.ebiom.2018.09.023

	Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study
	Liu, Fuquan 1; Ning, Zhenyuan 2,3; Liu, Yanna 2; Liu, Dengxiang 4; Tian, Jie 5; Luo, Hongwu 6; An, Weimin 7; Huang, Yifei 2; Zou, Jialiang 2; Liu, Chuan 2; Liu, Changchun 7; Wang, Lei 1; Liu, Zaiyi 8; Qi, Ruizhao 9; Zuo, Changzeng 4; Zhang, Qingge 4; Wang, Jitao 4; Zhao, Dawei 10; Duan, Yongli 11; Peng, Baogang 12; Qi, Xingshun 13; Zhang, Yuening 14; Yang, Yongping 15; Hou, Jinlin 2; Dong, Jiahong 16; Li, Zhiwei 9,17; Ding, Huiguo 14; Zhang, Yu 3; Qi, Xiaolong 2,16,18
发表期刊	EBIOMEDICINE
ISSN	2352-3964
	2018-10-01
卷号	36 页码:151-158
通讯作者	Ding, Huiguo(dinghuiguo@ccmu.edu.cn) ; Zhang, Yu(yuzhang@smu.edu.cn) ; Qi, Xiaolong(qixiaolong@vip.163.com)
摘要	Clinically significant portal hypertension (CSPH) is associated with an incremental risk of esophageal varices and overt clinical decompensations. However, hepatic venous pressure gradient (HVPG) measurement, the gold standard for defining CSPH (HVPG >= 10 mm Hg) is invasive and therefore not suitable for routine clinical practice. This study aims to develop and validate a radiomics-based model as a noninvasive method for accurate detection of CSPH in cirrhosis. The prospective multicenter diagnostic trial (CHESS1701, ClinicalTrials.gov identifier: NCT03138915) involved 385 patients with cirrhosis from five liver centers in China between August 2016 and September 2017. Patients who had both HVPG measurement and contrast-enhanced CT within 14 days prior to the catheterization were collected. The noninvasive radiomics model, termed rHVPG for CSPH was developed based on Cr images in a training cohort consisted of 222 consecutive patients and the diagnostic performance was prospectively assessed in 163 consecutive patients in four external validation cohorts. rHVPG showed a good performance in detection of CSPH with a C-index of 0.849 (95%CI: 0.786-0.911). Application of rHVPG in four external prospective validation cohorts still gave excellent performance with the C-index of 0.889 (95%CI: 0.752-1.000,0.800 (95%CI: 0.614-0.986), 0.917 (95%CI: 0.772-1.000), and 0.827 (95%CI: 0.618-1.000), respectively. Intraclass correlation coefficients for inter- and infra-observer agreement were 0.92-0.99 and 0.97-0.99, respectively. A radiomics signature was developed and prospectively validated as an accurate method for noninvasive detection of CSPH in cirrhosis. The tool of rHVPG assessment can facilitate the identification of CSPH rapidly when invasive transjugular procedure is not available. (C) 2018 The Authors. Published by Elsevier B.V.
关键词	Portal hypertension Liver cirrhosis Hepatic venous pressure gradient Radioinics Noninvasive
DOI	10.1016/j.ebiom.2018.09.023
关键词[WOS]	CHRONIC HEPATITIS-C ; PRESSURE-GRADIENT ; LIVER FIBROSIS ; ELASTOGRAPHY ; VARICES ; CANCER ; CARCINOMA ; BIOMARKER ; DISEASE ; IMAGES
收录类别	SCI
语种	英语
资助项目	National Natural Science Foundation of China[81600510] ; National Natural Science Foundation of China[81672725] ; Guangdong Science Fund for Distinguished Young Scholars[2018B030306019] ; Guangzhou Industry-Academia-Research Collaborative Innovation Major Project[201704020015] ; Special Funds for the Cultivation of Guangdong College Students' Scientific and Technological Innovation[pdjha0096] ; Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding[ZYLX201610] ; Beijing Municipal Administration of Hospitals' Ascent Plan[DFL20151602] ; Application Research on Clinical Characteristics of the Capital[z161100000516197] ; Capital's Funds for Health Improvement and Research[2018-1-2081] ; National Natural Science Foundation of China[81600510] ; National Natural Science Foundation of China[81672725] ; Guangdong Science Fund for Distinguished Young Scholars[2018B030306019] ; Guangzhou Industry-Academia-Research Collaborative Innovation Major Project[201704020015] ; Special Funds for the Cultivation of Guangdong College Students' Scientific and Technological Innovation[pdjha0096] ; Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding[ZYLX201610] ; Beijing Municipal Administration of Hospitals' Ascent Plan[DFL20151602] ; Application Research on Clinical Characteristics of the Capital[z161100000516197] ; Capital's Funds for Health Improvement and Research[2018-1-2081]
项目资助者	National Natural Science Foundation of China ; Guangdong Science Fund for Distinguished Young Scholars ; Guangzhou Industry-Academia-Research Collaborative Innovation Major Project ; Special Funds for the Cultivation of Guangdong College Students' Scientific and Technological Innovation ; Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding ; Beijing Municipal Administration of Hospitals' Ascent Plan ; Application Research on Clinical Characteristics of the Capital ; Capital's Funds for Health Improvement and Research
WOS研究方向	General & Internal Medicine ; Research & Experimental Medicine
WOS类目	Medicine, General & Internal ; Medicine, Research & Experimental
WOS记录号	WOS:000447685300023
出版者	ELSEVIER SCIENCE BV
引用统计	被引频次：54[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.ia.ac.cn/handle/173211/23056
专题	中国科学院分子影像重点实验室
通讯作者	Ding, Huiguo; Zhang, Yu; Qi, Xiaolong
作者单位	1.Capital Med Univ, Beijing Shijitan Hosp, Dept Intervent Therapy, CHESS Grp, Beijing, Peoples R China 2.Southern Med Univ, State Key Lab Organ Failure Res, Inst Hepatol, CHESS Grp,Hepat Hemodynam Lab,Nanfang Hosp, Guangzhou, Guangdong, Peoples R China 3.Southern Med Univ, Sch Biomed Engn, Guangzhou, Guangdong, Peoples R China 4.Xingtai Peoples Hosp, Xingtai Inst Canc Control, Xingtai, Peoples R China 5.Chinese Acad Sci, Key Lab Mol Imaging, Inst Automat, Beijing, Peoples R China 6.Cent S Univ, Dept Gen Surg, Xiangya Hosp 3, Changsha, Hunan, Peoples R China 7.302 Hosp PLA, Dept Radiol, Beijing, Peoples R China 8.Guangdong Acad Med Sci, Dept Radiol, Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China 9.302 Hosp PLA, Dept Gen Surg, Beijing, Peoples R China 10.Capital Med Univ, Dept Radiol, Beijing Youan Hosp, Beijing, Peoples R China 11.Capital Med Univ, Dept Radiol, Beijing Shijitan Hosp, Beijing, Peoples R China 12.Sun Yat Sen Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China 13.Gen Hosp Shenyang Mil Area, Dept Gastroenterol, Shenyang, Liaoning, Peoples R China 14.Capital Med Univ, Dept Gastroenterol & Hepatol, Beijing Youan Hosp, Beijing, Peoples R China 15.302 Hosp PLA, Ctr Therapeut Res Hepatocarcinoma, Beijing, Peoples R China 16.Tsinghua Univ, Beijing Tsinghua Changgung Hosp, Hepatopancreatobiliary Ctr, Sch Clin Med, Beijing, Peoples R China 17.Third Peoples Hosp Shenzhen, Dept Hepatobiliary Surg, Shenzhen, Peoples R China 18.Lanzhou Univ, CHESS Frontier Ctr, Lanzhou, Gansu, Peoples R China
推荐引用方式 GB/T 7714	Liu, Fuquan,Ning, Zhenyuan,Liu, Yanna,et al. Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study[J]. EBIOMEDICINE,2018,36:151-158.
APA	Liu, Fuquan.,Ning, Zhenyuan.,Liu, Yanna.,Liu, Dengxiang.,Tian, Jie.,...&Qi, Xiaolong.(2018).Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study.EBIOMEDICINE,36,151-158.
MLA	Liu, Fuquan,et al."Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701): a prospective multicenter study".EBIOMEDICINE 36(2018):151-158.